A new commentary in BMC Cancer warns that pan-cancer studies treating CFH as a single cancer biomarker have been measuring an ...
A comprehensive multi-omics study catalogues thousands of cancer-specific isoform switches in melanoma, ovarian cancer, and ...
Illumina, Inc. introduced SpliceAI2, a new genomic AI model designed to address one of the central challenges in genomics: understanding the functional consequences of genetic variation. SpliceAI2 ...
On Thursday, Akari Therapeutics said it filed a new PCT application covering its PH1 payload and its ability to disrupt multiple cancer-driving pathways through RNA splicing modul ...
Patent filing covers PH1 payload's unique ability to disrupt multiple cancer-driving pathways in addition to its overall cytotoxic mechanism Expands intellectual property portfolio supporting Akari's ...
Patent filing covers PH1 payload’s unique ability to disrupt multiple cancer-driving pathways in addition to its overall ...
Background Next-generation sequencing of cancer predisposition genes is routinely used in hereditary cancer diagnostics.
In June 2026, Boehringer signed a research collaboration agreement with Combotope Therapeutics to advance tumour-selective antibody therapies targeting cancer. "Boehringer and Envisagenics to develop ...
If you’re a cancer patient in the U.S. and have been seeking treatments, chances are you have at least started researching alternative treatments. After all, traditional healthcare is not 100% ...
Molecular basis of HACD-TECR complex mediated very-long-chain fatty acid elongation reveal a potential target in colorectal cancer MALT1 (mucosa-associated lymphoid tissue lymphoma/leukemia protein 1) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results